<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00015288</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-5-0013-10</org_study_id>
    <secondary_id>Y01-5-0013-10</secondary_id>
    <nct_id>NCT00015288</nct_id>
  </id_info>
  <brief_title>Buprenorphine and Naloxone Combination Study - 10</brief_title>
  <official_title>PK0496 Pharmacokinetics of Buprenorphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York MDRU</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine pharmacokinetics and dose proportionality of
      sublingual tablets containing varying doses of buprenorphine and naloxone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to examine pharmacokinetics and dose proportionality of
      sublingual tablets containing varying doses of buprenorphine and naloxone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1996</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physiological measures</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurements of buprenorphine and naloxone in plasma</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective symptoms measures</measure>
  </primary_outcome>
  <enrollment>0</enrollment>
  <condition>Heroin Dependence</condition>
  <condition>Opioid-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male/Female between the ages of 21 and 45. Within 15% of ideal body weight. No oral
        pathology that would interfere with the sublingual absorption of the medication.
        Experienced in the use of opiates but not dependent.

        Exclusion Criteria:

        LFT's exceeding than 3x's normal. History of seizure. Opiate dependent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Rotrosen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York MDRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York MDRU</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 1998</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2001</study_first_submitted>
  <study_first_submitted_qc>April 17, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2001</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

